Overview Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Status: Not yet recruiting Trial end date: 2025-09-01 Target enrollment: Participant gender: Summary This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study. Phase: Phase 1 Details Lead Sponsor: Atridia Pty Ltd.